Unmasking a killer: DNA O6-methylguanine and the cytotoxicity of methylating agents

Mutation Research - Reviews in Mutation Research

Volumn 462, Issue 2-3, 2000, Pages 71-82

  Bignami, M ^a   O'Driscoll, M ^b   Aquilina, G ^a   Karran, P ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Cytotoxicity; Mismatch repair; Mutation induction; O6 methylguanine

Indexed keywords

2 AMINOPURINE; 6 O METHYLGUANINE; ALKYLATING AGENT; DACARBAZINE; DIMETHYLHYDRAZINE; DIMETHYLNITROSAMINE; ETHYLNITROSOUREA; MESYLIC ACID METHYL ESTER; METHYLNITRONITROSOGUANIDINE; METHYLNITROSOUREA; TEMOZOLOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; BASE MISPAIRING; CANCER; CARCINOGENESIS; CYTOTOXICITY; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; ESCHERICHIA COLI; KNOCKOUT MOUSE; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALIA; ESCHERICHIA COLI; MAMMALIA;

EID: 0034027358     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5742(00)00016-8     Document Type: Article

References (63)

1. Swann P.F., Magee P.M. Nitrosamine-induced carcinogenesis. The alkylation of nucleic acids of the rat by N-methyl-N-nitrosourea, dimethylnitrosamine, dimethyl sulphate and methyl methanesulphonate. Biochem. J. 110:1968;39-47.
2. 6 alkylation of deoxyguanosine to mutagenicity of nitrosamines and nitrosamides. Nature. 223:1969;206-208.
3. 6-ethylguanine in rat brain DNA: correlation with nervous system specific carcinogenesis by ethylnitrosourea. Proc. Natl. Acad. Sci. U. S. A. 71:1974;639-643.
4. 6-methylguanine. Biochim. Biophys. Acta. 562:1979;51-61.
5. - Escherichia coli to N-methyl-N′-nitro-N-nitrosoguanidine. Mol. Gen. Genet. 209:1987;526-532.
6. Karran P., Bignami M. Self-destruction and tolerance in resistance of mammalian cells to alkylation damage. Nucleic Acids Res. 20:1992;2933-2940.
7. Samson L., Cairns J. A new pathway for DNA repair in Escherichia coli. Nature. 267:1977;281-283.
8. Sedgwick B. Molecular cloning of a gene which regulates the adaptive response to alkylating agents in Escherichia coli. Mol. Gen. Genet. 191:1983;466-472.
9. Lindahl T., Sedgwick B., Sekiguchi M. Regulation and expression of the adaptive response to alkylating agents. Annu. Rev. Biochem. 57:1988;133-157.
10. 6-methylguanine lesions in methylated DNA. Nucleic Acids Res. 9:1981;3089-3103.
11. 6-methylguanine from DNA by human liver fractions. Proc. Natl. Acad. Sci. U. S. A. 79:1982;5162-5165.
12. 6-methylguanine-DNA methyltransferase of human lymphoid cells:structural and kinetic properties and absence in repair-deficient cells. Cancer Res. 43:1983;3247-3252.
13. 6-methylguanine from DNA. Cancer Res. 40:1980;452-458.
14. Cooper D.P., O'Connor P.J., Margison G.P. Effect of acute doses of 2-acetylaminofluorene on the capacity of rat liver to repair methylated purines in DNA in vivo and in vitro. Cancer Res. 42:1982;4203-4209.
15. 6-methylguanine. Proc. Natl. Acad. Sci. U. S. A. 87:1990;686-690.
16. 6-methylguanine-DNA methyltransferase. J. Biol. Chem. 265:1990;9563-9569.
17. 6-methylguanine in DNA. J. Mol. Biol. 213:1990;739-747.
18. R. Montesano, J. Hall, C.P. Wild, Alkylating agents relating to carcinogenesis in man. In: Relevance of animal studies to the evaluation of human risk, Prog. Clin. Biol. Res. 374 (1992) 175-196.
19. Day R.S., Ziolkowski C.H.J., Scudiero D.A., Meyer S., Lubiniecki A.S., Girardi A.J., Galloway S.M., Bynum G.D. Defective repair of alkylated DNA by human tumour and SV40-transformed cell strains. Nature. 288:1980;724-727.
20. 6-methylguanine from DNA of normal and xeroderma pigmentosum-derived lymphoblastoid lines. Nature. 289:1981;417-420.
21. Day R.S., Ziolkowski C.H.J. Human brain tumour cell strains with deficient host- cell reactivation of N-methyl-N′-nitro-N-nitrosoguanidine-damaged adenovirus 5. Nature. 279:1979;797-799.
22. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res. 50:1990;6119-6129.
23. 6-methylguanine-DNA methyltransferase in human fibroblasts increases the mutagenic response to N-methyl-N′-nitro-N-nitrosoguanidine. Carcinogenesis. 6:1985;1823-1826.
24. Karran P., Bignami M. DNA damage tolerance, mismatch repair and genome instability. BioEssays. 16:1994;833-839.
25. Samson L., Derfler B., Waldstein E. Suppression of human DNA alkylation-repair defects by Escherichia coli DNA repair genes. Proc. Natl. Acad. Sci. U. S. A. 83:1986;5607-5610.
26. Brennand J., Margison G.P. Reduction of the toxicity and mutagenicity of alkylating agents in mammalian cells harbouring the Escherichia coli alkyltransferase gene. Proc. Natl. Acad. Sci. U. S. A. 83:1986;6292-6296.
27. 6-alkylguanine alkyltransferase reduces the toxic effect of alkylating agents. Carcinogenesis. 7:1986;2081-2084.
28. Kataoka H., Hall J., Karran P. Complementation of sensitivity to alkylating agents in Escherichia coli and Chinese hamster ovary cells by expression of a cloned bacterial DNA repair gene. EMBO J. 5:1986;3195-3200.
29. Aquilina G., Ceccotti S., Martinelli S., Hampson R., Bignami M. CCNU-sensitivity in mismatch repair defective human cells. Cancer Res. 58:1998;135-141.
30. Karran P., Bignami M. Drug-related killings: a case of mistaken identity. Chem. Biol. 3:1996;875-879.
31. Branch P., Aquilina G., Bignami M., Karran P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature. 362:1993;652-654.
32. Kat A., Thilly W.G., Fang W.H., Longley M.J., Li G.M., Modrich P. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc. Natl. Acad. Sci. U. S. A. 90:1993;6424-6428.
33. Koi M., Umar A., Chauhan D.P., Cherian S.P., Carethers J.M., Kunkel T.A., Boland C.R. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res. 54:1994;4308-4312.
34. Branch P., Hampson R., Karran P. DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. Cancer Res. 55:1995;2304-2309.
35. Umar A., Koi M., Risinger J.I., Glaab W.E., Tindall K.R., Kolodner R.D., Boland S.C.R., Barett J.C., Kunkel T.A. Correction of hypermutability, N-methyl-N′-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res. 57:1997;3949-3955.
36. Radman M., Wagner R. Mismatch repair in E. coli. Annu. Rev. Genet. 20:1986;523-538.
37. - mutants of Escherichia coli: a role for 6-methyladenine in mutation avoidance. Mol. Gen. Genet. 163:1978;307-312.
38. 6-methylguanine residues in E. coli DNA. Nature. 296:1982;868-869.
39. Dosanjh M.K., Roy R., Mitra S., Singer B. 1,N6-ethenoadenine is preferred over 3-methyladenine as substrate by a cloned human N-methylpurine-DNA glycosylase (3-methyladenine-DNA glycosylase). Biochemistry. 33:1994;1624-1628.
40. Saparbaev M., Laval J. Excision of hypoxanthine from DNA containing dIMP residues by the Escherichia coli, yeast, rat, and human alkylpurine DNA glycosylases. Proc. Natl. Acad. Sci. U. S. A. 91:1994;5873-5877.
41. Karran P., Lindahl T., Ofsteng I., Evensen G.B., Seeberg E. Escherichia coli mutants deficient in 3-methyladenine-DNA glycosylase. J. Mol. Biol. 140:1980;101-127.
42. Evensen G., Seeberg E. Adaptation to alkylation resistance involves the induction of a DNA glycosylase. Nature. 296:1982;773-775.
43. Kungland A., Fairbairn L., Watson A.J., Margison G.P., Seeberg E. Expression of the E. coli 3-methyladenine-DNA glycosylase I gene in mammalian cells reduces the toxic and mutagenic effects of methylating agents. EMBO J. 11:1992;4439-4444.
44. Coquerelle T., Dosch J., Kaina B. Overexpression of N-methylpurine-DNA glycosylase in Chinese hamster ovary cells renders them more sensitive to the production of chromosomal aberrations by methylating agents - a case in imbalanced DNA repair. Mutat. Res. 336:1995;9-17.
45. Engelward B.P., Dreslin A., Christensen J., Huszar D., Kurahara C., Samson L. Repair-deficient 3-methyladenine DNA glycosylase homozygous mutant mouse cells have increased sensitivity to alkylation-induced chromosome damage and cell killing. EMBO J. 15:1996;945-952.
46. Elder R.H., Jansen J.G., Weeks R.J., Willington M.A., Deans B., Watson A.J., Mynett K.J., Bailey J.A., Cooper D.P., Rafferty J.A., Heeran M.C., Wijnhoven S.W.P., van Zeeland A.A., Margison G.P. Alkylpurine-DNA-N-glycosylase knockout mice show increased susceptibility to induction of mutations by methyl methanesulfonate. Mol. Cell. Biol. 18:1998;5828-5837.
47. Kawate H., Sakumi K., Tsuzuki T., Nakatsuru Y., Ishikawa T., Takahashi S., Noda H.T., Sekiguchi M. Separation of killing and tumorigenic effects of an alkylating agent in mice defective in two of the DNA repair genes. Proc. Natl. Acad. Sci. U. S. A. 95:1998;5116-5120.
48. Sobol R.W., Horton J.K., Kühn R., Gu H., Singhal R.K., Prasad R., Rajewsky K., Wilson S.H. Requirement of mammalian DNA polymerase-β in base-excision repair. Nature. 379:1996;183-186.
49. Ochs K., Sobol R.W., Wilson S.H., Kaina B. Cells deficient in DNA polymerase β are hypersensitive to alkylating agent-induced apoptosis and chromosomal breakage. Cancer Res. 59:1999;1544-1551.
50. Humbert O., Fiumincino S., Aquilina G., Branch P., Oda S., Zijno A., Karran P., Bignami M. Mismatch repair and differential sensitivity of mouse and human cells to methylating agents. Carcinogenesis. 20:1999;205-214.
51. Glaab W.E., Risinger J.I., Umar A., Barrett J.C., Kunkel T.A., Tindall K.R. Resistance to 6-thioguanine in mismatch repair-deficient human cancer cell lines correlates with an increase in induced mutations at the HPRT locus. Carcinogenesis. 19:1998;1931-1937.
52. Glaab W.E., Skopek T.R. Cytotoxic and mutagenic response of mismatch repair-defective human cancer cells exposed to a food-associated heterocyclic amine. Carcinogenesis. 20:1999;391-394.
53. Glaab W.E., Risinger J.I., Umar A., Barrett J.C., Kunkel T.A., Tindall K.R. Cellular resistance and hypermutability in mismatch repair-deficient human cancer cell lines following treatment with methyl methanesulfonate. Mutat. Res. 398:1998;197-207.
54. Andrew S.E., McKinnon M., Cheng B.S., Francis A., Penney J., Reitmar A.H., Mak T.W., Jirik F.R. Tissues of MSH2-deficient mice demonstrate hypermutability on exposure to a DNA methylating agent. Proc. Natl. Acad. Sci. U. S. A. 95:1998;1126-1130.
55. Toft N.J., Winton D.J., Kelly J., Howard L.A., Dekker M., te Riele H., Arends M.J., Wyllie A.H., Margison G.P., Clarke A.R. Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. Proc. Natl. Acad. Sci. U. S. A. 96:1999;3911-3915.
56. de Wind N., Dekker M., van Rossum A., van der Valk M., te Riele H. Mouse models for hereditary nonpolyposis colorectal cancer. Cancer Res. 58:1998;248-255.
57. Tricker A.R., Preussmann R. Carcinogenic N-nitrosamines in the diet: occurrence, formation, mechanisms and carcinogenic potential. Mutat. Res. 259:1991;277-289.
58. Ziebarth D., Spiegelhalder B., Bartsch H. N-nitrosation of medicinal drugs catalysed by bacteria from human saliva and gastro-intestinal tract, including Helicobacter pylori. Carcinogenesis. 18:1997;383-389.
59. Ohshima H., Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat. Res. 305:1994;253-264.
60. Ohshima H., Tsuda M., Adachi H., Ogura T., Sugimura T., Esumi H. L-Arginine-dependent formation of N-nitrosamines by the cytosol of macrophages activated with lipopolysaccharide and interferon-gamma. Carcinogenesis. 12:1991;1217-1220.
61. Sartor R.B. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol. Clin. North Am. 24:1995;475-507.
62. Brentnall T.A., Crispin D.A., Bronner M.P., Cherian S.P., Hueffed M., Rabinovitch P.S., Rubin C.E., Haggitt R.C., Boland C.R. Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res. 56:1996;1237-1240.
63. Kane M.F., Loda M., Gaida G.M., Lipman J., Mishra R., Goldman H., Jessup J.M., Kolodner R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 57:1997;808-811.